Elanco Animal Health (NYSE:ELAN) CEO Jeffrey Simmons Acquires 4,971 Shares of Stock

Elanco Animal Health Incorporated (NYSE:ELAN) CEO Jeffrey Simmons bought 4,971 shares of the business’s stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the transaction, the chief executive officer owned 171,971 shares of the company’s stock, valued at $3,454,897.39. This trade represents a 2.98% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Elanco Animal Health Stock Down 0.8%

Shares of NYSE ELAN opened at $19.78 on Wednesday. The firm has a market cap of $9.88 billion, a price-to-earnings ratio of -39.55, a PEG ratio of 2.14 and a beta of 1.69. The company has a quick ratio of 1.12, a current ratio of 2.16 and a debt-to-equity ratio of 0.60. Elanco Animal Health Incorporated has a 52-week low of $12.40 and a 52-week high of $27.72. The business’s 50 day moving average is $23.16 and its two-hundred day moving average is $23.31.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The business had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same quarter in the prior year, the company earned $0.37 earnings per share. The company’s revenue was up 14.9% on a year-over-year basis. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. Research analysts predict that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Hedge Funds Weigh In On Elanco Animal Health

Several large investors have recently bought and sold shares of ELAN. NewEdge Advisors LLC boosted its stake in Elanco Animal Health by 133.7% in the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock valued at $25,000 after acquiring an additional 627 shares in the last quarter. Huntington National Bank boosted its stake in Elanco Animal Health by 136.7% in the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock valued at $38,000 after acquiring an additional 1,087 shares in the last quarter. Root Financial Partners LLC boosted its stake in Elanco Animal Health by 50.7% in the fourth quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. acquired a new position in Elanco Animal Health in the fourth quarter valued at $41,000. Finally, Whittier Trust Co. of Nevada Inc. boosted its stake in Elanco Animal Health by 80.3% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Wall Street Analysts Forecast Growth

ELAN has been the topic of a number of recent research reports. Morgan Stanley upped their price objective on Elanco Animal Health from $22.00 to $24.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 25th. Leerink Partners upped their price objective on Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. Weiss Ratings lowered Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, May 11th. KeyCorp upped their price objective on Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Finally, Piper Sandler raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Elanco Animal Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.20.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.